Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

South African President Addresses Increased Access To Antiretrovirals, Reduction In HIV Incidence
South African President Jacob Zuma on Wednesday said he wants to have 80 percent of HIV-positive South Africans who need antiretrovirals (ARVs) on them by 2011, BuaNews reports (BuaNews/allAfrica.com, 6/3). The announcement was part of Zuma"s first state-of-the-nation address, when he discussed ways the government would strive to "step up measures to improve health care in Africa"s strongest economy," Reuters writes. "We have set ourselves the goals of reducing inequalities in health care ... and step up the fight against the scourge of HIV and AIDS, TB and other diseases," Zuma said (Roelf, Reuters, 6/4).
generic viagra online
Study Demonstrated Once-Daily Vyvanse(R) CII Provided Significant Improvement Of ADHD Symptoms For Children At 13 Hours After Administration
Shire plc announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration. In this pediatric analog classroom study, treatment with Vyvanse was associated with significant improvement in behavior and attention in children at each time point measured, with improvement at 13 hours after administration.
News of the day
VOA News Examines International HIV/AIDS Implementers Meeting
VOA News examines the 2009 HIV/AIDS Implementers Meeting in Windhoek, Namibia, which recently brought together 1,500 people from 55 countries to compare notes on HIV/AIDS programs around the world. The article features comments by Assistant U.S. Global AIDS Coordinator Michele Moloney-Kitts who attended and shared some of her experiences from the meeting.
Health Insurance

Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a For Relapsing Multiple Sclerosis

Biogen Idec (NASDAQ: BIIB) announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). Biogen Idec is currently enrolling patients in a global Phase III study evaluating the efficacy and safety of either bi-weekly or once-monthly injections of PEGylated interferon beta-1a in this patient population. "Early-stage clinical trials suggest that PEGylated interferon beta-1a has the potential to offer less frequent dosing without compromising efficacy, which would be a significant development for people living with multiple sclerosis," said Michael Panzara, M.D., M.P.H., vice president and chief medical officer of neurology at Biogen Idec. "We look forward to working closely with the FDA to expedite the compound"s development and review process." The FDA"s Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Biogen Idec plans to enroll more than 1,200 patients in the Phase III, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of PEGylated interferon beta-1a in patients with RMS. The global trial, called ADVANCE, will determine the efficacy of PEGylated interferon beta-1a in reducing relapse rates in patients with RMS at one year. The study will also examine if, over time, treatment with PEGylated interferon beta-1a can slow disease progression and lead to a decrease in the number of T2 hyperintense brain lesions commonly seen in MS patients. Biogen Idec


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009